Impact of the 2013 ASCO/CAP HER2 revised guidelines on HER2 results in breast core biopsies with invasive breast carcinoma: a retrospective study

被引：9

作者：

Overcast, Wynton B. ^{[1
]}

Zhang, Jianying ^{[2
]}

Zynger, Debra L. ^{[3
]}

Tozbikian, Gary H. ^{[3
]}

机构：

[1] Ohio State Univ, Coll Med, 410 W 10th Ave,E410 Doan Hall, Columbus, OH 43210 USA

[2] Ohio State Univ, Ctr Biostat, 320 Lincoln Tower,1800 Cannon Dr, Columbus, OH 43210 USA

[3] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 W 10th Ave,E410 Doan Hall, Columbus, OH 43210 USA

来源：

VIRCHOWS ARCHIV | 2016年 / 469卷 / 02期

关键词：

ASCO/CAP guidelines; Breast cancer; Equivocal category; HER2 immunohistochemistry (IHC); HER2 fluorescence in situ hybridization (FISH); IN-SITU HYBRIDIZATION; POLYMERASE CHAIN-REACTION; CLINICAL ONCOLOGY/COLLEGE; AMERICAN SOCIETY; COPY NUMBER; CANCER; RECEPTOR; IMMUNOHISTOCHEMISTRY; TRASTUZUMAB; FISH;

D O I：

10.1007/s00428-016-1951-8

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

[No abstract available]

引用

页码：203 / 212

页数：10

共 26 条

[1] Issues and updates: evaluating estrogen receptor-α, progesterone receptor, and HER2 in breast cancer [J].

Allred, D. Craig .

MODERN PATHOLOGY, 2010, 23 :S52-S59

[2]

[Anonymous], 2007, J CLIN ONCOL

[3] Stemming Resistance to HER-2 Targeted Therapy [J].

Bedard, Philippe L. ;

Cardoso, Fatima ;

Piccart-Gebhart, Martine J. .

JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2009, 14 (01) :55-66

[4] Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization [J].

Bethune, Gillian C. ;

van Zanten, Daniel Veldhuijzen ;

MacIntosh, Rebecca F. ;

Rayson, Daniel ;

Younis, Tallal ;

Thompson, Kara ;

Barnes, Penny J. .

HISTOPATHOLOGY, 2015, 67 (06) :880-887

[5] Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network [J].

Borley, A. ;

Mercer, T. ;

Morgan, M. ;

Dutton, P. ;

Barrett-Lee, P. ;

Brunelli, M. ;

Jasani, B. .

BRITISH JOURNAL OF CANCER, 2014, 110 (08) :2139-2143

[6]

Chang J, 2009, DIS BREAST, P443

[7] High False- Negative Rate of HER2 Quantitative Reverse Transcription Polymerase Chain Reaction of the Oncotype DX Test: An Independent Quality Assurance Study [J].

Dabbs, David J. ;

Klein, Molly E. ;

Mohsin, Syed K. ;

Tubbs, Raymond R. ;

Shuai, Yongli ;

Bhargava, Rohit .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4279-4285

[8] Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial [J].

Dowsett, Mitch ;

Procter, Marion ;

McCaskill-Stevens, Worta ;

de Azambuja, Evandro ;

Dafni, Urania ;

Rueschoff, Josef ;

Jordan, Bruce ;

Dolci, Stella ;

Abramovitz, Mark ;

Stoss, Oliver ;

Viale, Giuseppe ;

Gelber, Richard D. ;

Piccart-Gebhart, Martine ;

Leyland-Jones, Brian .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2962-2969

[9] Correlation Between HER2 Determined by Fluorescence In Situ Hybridization and Reverse Transcription-Polymerase Chain Reaction of the Oncotype DX Test [J].

Dvorak, Leah ;

Dolan, Michelle ;

Fink, James ;

Varghese, Linda ;

Henriksen, Jonathan ;

Gulbahce, H. Evin .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2013, 21 (03) :196-199

[10]

Epstein M, 2009, DIS BREAST

← 1 2 3 →